UgandaTuberculosis profile
Population  2016 41 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 11 (5.8–17) 26 (14–41)
Mortality (HIV+TB only) 14 (8.3–22) 35 (20–53)
Incidence  (includes HIV+TB) 83 (49–127) 201 (118–306)
Incidence (HIV+TB only) 35 (20–54) 85 (49–131)
Incidence (MDR/RR-TB)** 1.9 (0.98–2.9) 4.7 (2.4–7)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 4 (2.2–5.9) 19 (10–28) 23 (12–33)
Males 4.6 (2.5–6.8) 56 (30–82) 61 (32–89)
Total 8.7 (4.6–13) 75 (40–110) 83 (49–127)
TB case notifications, 2016  
Total cases notified 44 816
Total new and relapse 43 413
          - % tested with rapid diagnostics at time of diagnosis 24%
          - % with known HIV status 94%
          - % pulmonary 92%
          - % bacteriologically confirmed among pulmonary 68%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 52% (34–88)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.32 (0.16–0.51)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 18 225 43%
          - on antiretroviral therapy 16 403 90%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 000
(590–1 400)
Estimated % of TB cases with MDR/RR-TB 1.6% (0.78–2.4) 12% (3.4–21)  
% notified tested for rifampicin resistance 15% 50% 12 065
MDR/RR-TB cases tested for resistance to second-line drugs   101
Laboratory-confirmed cases MDR/RR-TB: 489, XDR-TB: 4
Patients started on treatment **** MDR/RR-TB: 374, XDR-TB: 4
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 75% 41 516
Previously treated cases, excluding relapse, registered in 2015 67% 2 114
HIV-positive TB cases registered in 2015 75% 16 948
MDR/RR-TB cases started on second-line treatment in 2014 71% 214
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
5.2% (4.8–5.7)
TB financing, 2017  
National TB budget (US$ millions) 54
Funding source: 3% domestic, 26% international, 71% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-20 Data: www.who.int/tb/data